California Public Employees Retirement System held its stake in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,000 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. California Public Employees Retirement System owned about 0.20% of Dicerna Pharmaceuticals worth $130,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Renaissance Technologies LLC grew its stake in Dicerna Pharmaceuticals by 2.4% in the first quarter. Renaissance Technologies LLC now owns 418,500 shares of the biopharmaceutical company’s stock worth $1,423,000 after purchasing an additional 9,818 shares in the last quarter. Vanguard Group Inc. grew its stake in Dicerna Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock worth $1,078,000 after purchasing an additional 14,517 shares in the last quarter. Bourgeon Capital Management LLC grew its stake in Dicerna Pharmaceuticals by 188.9% in the second quarter. Bourgeon Capital Management LLC now owns 39,000 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 25,500 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Dicerna Pharmaceuticals by 6.1% in the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 2,094 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Dicerna Pharmaceuticals Inc (DRNA) opened at $8.54 on Monday. Dicerna Pharmaceuticals Inc has a 52 week low of $2.42 and a 52 week high of $10.24.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.22). Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 293.25%. The company had revenue of $0.47 million during the quarter. During the same period in the prior year, the firm posted ($0.68) EPS. The firm’s revenue for the quarter was up 192.6% compared to the same quarter last year. equities research analysts predict that Dicerna Pharmaceuticals Inc will post -3.04 EPS for the current fiscal year.

A number of equities analysts recently commented on the company. Zacks Investment Research downgraded Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. ValuEngine upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, November 2nd. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target (up from $6.00) on shares of Dicerna Pharmaceuticals in a research note on Friday, November 3rd. Finally, Chardan Capital reiterated a “hold” rating on shares of Dicerna Pharmaceuticals in a research note on Monday, August 14th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $6.81.

ILLEGAL ACTIVITY NOTICE: “Dicerna Pharmaceuticals Inc (DRNA) Position Maintained by California Public Employees Retirement System” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/dicerna-pharmaceuticals-inc-drna-position-maintained-by-california-public-employees-retirement-system/1742265.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Institutional Ownership by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.